The lips are among the most pain-sensitive areas of the face—rich in sensory nerve endings, densely vascularized, and covered by thin, highly mobile mucosa. This anatomical reality means that discomfort during injection and post-procedural swelling can significantly influence a patient’s decision to pursue lip augmentation. While many prospective patients delay treatment due to fear of pain, modern dermal filler design offers evidence-based strategies to meaningfully improve procedural comfort—not through stoicism, but through intentional engineering of material composition, delivery systems, and biophysical properties.
Ruizhi Feiran (registered under China NMPA approval number 20233131478) is a hyaluronic acid (HA) filler specifically indicated for volume enhancement of the vermilion border and vermilion body. Its development emphasizes three integrated comfort-enhancing features: a triphasic lidocaine release system, BioBT2.0 isotonic technology, and an ergonomically engineered injection device—each targeting distinct phases of the patient experience: needle insertion, gel deposition, and early postoperative recovery.
Where Does Lip Injection Discomfort Originate?
Pain during lip augmentation arises from three sequential physiological events:
Needle insertion—The thin epithelium of the vermilion and its transition zone with adjacent skin offer minimal mechanical resistance. Consequently, even minor needle trauma triggers robust nociceptive signaling. Feiran is supplied with BD Hylok pre-filled syringes fitted with 30-gauge needles—significantly finer than standard 27-gauge options—reducing tissue disruption at entry.
Gel deposition—As HA gel is injected into the relatively dense submucosal plane, intratissue pressure rises. High-viscosity formulations without optimized delivery mechanics may require excessive manual force, leading to inconsistent flow rates and localized pressure spikes that patients perceive as sharp, transient pain. Feiran incorporates a patented ergonomic assist device designed to lower injection resistance and enhance dose precision—minimizing operator-induced variability and associated discomfort.
Early postoperative phase (24–72 hours)—Swelling, tenderness, and a sensation of fullness are nearly universal after lip injection due to the region’s loose connective tissue architecture and high vascularity. However, the degree and duration of edema correlate strongly with the filler’s osmotic behavior. Excessive water uptake amplifies swelling peaks and prolongs functional recovery—including speech, eating, and social reintegration.
Triphasic Lidocaine Release: Beyond Simple Incorporation
Feiran contains 3 mg/mL of lidocaine hydrochloride—but not as a conventional additive. Its lidocaine is structurally integrated into the HA matrix using a triphasic release mechanism:
- Free-phase lidocaine: Immediately bioavailable upon injection, providing rapid onset analgesia during needle penetration and initial gel deposition.
- Surface-anchored lidocaine: Bound to the outer network surface, releasing gradually over several hours to mitigate early post-injection stinging and tenderness.
- Embedded-phase lidocaine: Covalently integrated within the crosslinked HA scaffold, enabling sustained release over approximately 24 hours—supporting comfort during peak inflammatory activity.
Clinical observations supporting this design appear in a peer-reviewed case series published in *Chinese Aesthetic Medicine* (2020;10(11):62–65), which documented outcomes in 82 female patients undergoing lip augmentation with this same lidocaine-releasing HA platform.
Isotonic Design: Mitigating Swelling at the Biophysical Level
Feiran employs BioBT2.0 intelligent dialysis technology to achieve near-physiological osmolarity (matching interstitial fluid) and a pH of 6.5–7.5. This isotonic profile minimizes osmotic water influx into the injected gel, thereby reducing early postoperative swelling magnitude and duration. While individual factors—including injection volume, depth, baseline vascularity, and post-treatment care—remain influential, isotonic formulation provides a foundational physical advantage for predictable recovery. Patients often cite “being able to return to work or social activities the next day” as a key practical benefit.
Ergonomic Delivery: The Unseen Influence on Patient Experience
Feiran’s BD Hylok pre-filled syringe includes a proprietary ergonomic assist mechanism. Though invisible to the patient, this feature enhances injection consistency by stabilizing plunger force and improving tactile feedback for the injector. More uniform gel distribution reduces the risk of nodules, asymmetry, and focal pressure-related discomfort—contributing indirectly but meaningfully to both procedural tolerance and aesthetic outcome.
Comparative Context Among Lip-Specific Fillers
While other HA fillers are used off-label or approved for lip enhancement—including Juvéderm Volbella® (with lidocaine, optimized for fine lines and subtle volume), RHA® Kiss (designed for dynamic facial regions using resilient hyaluronic acid technology), and Belotero® Lips (utilizing CPM—cohesive polydensified matrix—technology for smooth integration)—Feiran distinguishes itself by integrating all three comfort-focused innovations—triphase lidocaine, isotonicity, and lip-specific delivery—into a single, regulatory-cleared product. It does not require adjunctive topical anesthesia or procedural modifications to deliver its intended comfort profile.
Preparing for Your Consultation: Key Questions About Comfort
To optimize shared decision-making, patients should discuss the following with their provider before treatment:
- Medical history: Prior injectable experiences, personal pain threshold, and any known allergy or sensitivity to local anesthetics.
- Pre-procedure preparation: Whether topical anesthetic, ice application, or regional nerve block will be used—and how each option affects onset time, duration, and procedural workflow.
- Recovery expectations: Anticipated timing of peak swelling, guidance on oral intake, lip hygiene, and cosmetic use.
- Follow-up planning: Timing of post-treatment assessment, criteria for touch-up, and management protocols for adverse events such as overcorrection or persistent asymmetry.
Clinical Evidence Supporting Overall Satisfaction
In its pivotal randomized controlled trial involving 150 subjects, Feiran demonstrated high levels of composite satisfaction:
- At 6 months, 99% of participants rated their global aesthetic improvement as “good” or “excellent” per the Global Aesthetic Improvement Scale (GAIS).
- At 12 months, over 60% continued to report clinically meaningful enhancement in lip volume and contour.
Although the study did not isolate a standalone “comfort score,” the GAIS reflects holistic evaluation—including procedural tolerability, recovery trajectory, and final aesthetic result. These findings suggest that, under standardized clinical conditions, the integrated comfort features contribute meaningfully to overall patient acceptance.
Conclusion
Lip augmentation need not be defined by discomfort. Advances in biomaterial science now allow clinicians to address pain perception across multiple domains: molecular (lidocaine kinetics), biophysical (osmotic equilibrium), and mechanical (ergonomic delivery). Feiran represents a purpose-built solution—combining these elements into a single, NMPA-approved product for vermilion enhancement. For patients prioritizing comfort, these features provide concrete, discussion-ready parameters during consultation. As with all aesthetic interventions, treatment must be performed by qualified professionals in licensed medical settings to ensure safety, efficacy, and optimal outcomes.